SELECTIVE NECK DISSECTION FOLLOWING ADJUVANT THERAPY FOR ADVANCED HEAD AND NECK CANCER

被引:23
|
作者
Mukhija, Vijay [1 ]
Gupta, Sachin [1 ]
Jacobson, Adam S. [1 ,2 ]
Eloy, Jean Anderson [1 ]
Genden, Eric M. [1 ,2 ]
机构
[1] Mt Sinai Sch Med, Dept Otolaryngol Head & Neck Surg, New York, NY USA
[2] Mt Sinai Med Ctr, Head & Neck Canc Ctr, New York, NY 10029 USA
关键词
selective neck dissection; postchemoradiation neck dissection; postradiation neck dissection; head and neck cancer; SQUAMOUS-CELL CARCINOMA; UPPER AERODIGESTIVE TRACT; CERVICAL NODE METASTASES; DEFINITIVE CHEMORADIOTHERAPY; CONCURRENT CHEMOTHERAPY; OROPHARYNGEAL CANCER; CHEMORADIATION; DISEASE; MANAGEMENT; PATTERNS;
D O I
10.1002/hed.20944
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. In the past, surgeons believed that in order to eradicate regional disease, a radical or modified radical neck dissection was necessary. An evolution in surgical principles and the popularization of primary chemoradiation has raised the questions regarding the role of neck dissection and the extent of neck dissection following therapy. The aim of this study was to determine the efficacy of selective neck dissection (SND) for patients with N2 or N3 disease following treatment with primary radiation therapy or chemoradiation. Methods. A retrospective review of 58 patients with stage III or IV head and neck squamous cell carcinoma was conducted. The primary sites included base of tongue (n = 15) hypopharynx (n 12), tonsil (n = 16), larynx (n = 11), and unknown primary (n 4). Definitive treatment consisted of either concomitant chemoradiation (67.2%) or external beam radiation therapy (32.8%). In the monotherapy group, all patients received a total curative dose of 66 to 72 Gy in once-daily fractions of 180 to 200 cGy. The combined chemoradiation group received a similar radiation schedule and a 4-day continuous infusion of cisplatin (20 mg/m(2)/day) and 5-fluorouracil (1000 mg/m(2)/day). A planned SND of levels 11 to IV was performed on all the patients 3 to 6 weeks after completion of definitive medical therapy. Results. Seventy neck dissections were performed on 58 patients with advanced neck disease following radiation or chemoradiation. The median time of follow-up was 34 months (range, 9-71 months) following the neck dissection. Pathologically, 22.4% (13/58) of the patients had viable tumor cells identified in the neck dissection specimen. Seventy-two percent of the patients are currently alive, and 28% died as a result of distant disease, local or regional recurrence, or other causes. Of patients who died from distant disease, 11% had pathological evidence of residual tumor cells identified in the neck dissection specimen. Of patients who died from local or regional disease, 50% had pathological evidence of residual tumor cells identified in the neck dissection specimen. Conclusion. The rate of regional recurrence following SND is similar to reported rates following modified/radical neck dissection. This suggests that SND provides an appropriate surgical option for advanced neck disease in select patients following adjuvant therapy. (C) 2008 Wiley Periodicals, Inc. Head Neck 31: 183-188, 2009
引用
收藏
页码:183 / 188
页数:6
相关论文
共 50 条
  • [31] Head and neck cancer: From the radical neck dissection (RND) to the selective (SND) and radical modified neck dissection (RMND)
    Luboinski, B
    Mamelle, G
    Bosq, J
    [J]. EUROPEAN JOURNAL OF CANCER, 1999, 35 : S383 - S383
  • [32] SELECTIVE NECK DISSECTION IN THE MANAGEMENT OF THE NECK AFTER (CHEMO)RADIOTHERAPY FOR ADVANCED HEAD AND NECK CANCER. PROPOSAL FOR A CLASSIFICATION UPDATE COMMENTARY
    Robbins, K. Thomas
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2010, 32 (06): : 820 - 820
  • [33] A novel neck brace to characterize neck mobility impairments following neck dissection in head and neck cancer patients
    Chang, Biing-Chwen
    Zhang, Haohan
    Long, Sallie
    Obayemi, Adetokunbo
    Troob, Scott H.
    Agrawal, Sunil K.
    [J]. WEARABLE TECHNOLOGIES, 2021, 2
  • [34] Therapy for locoregionally advanced head and neck cancer
    Vokes, EE
    [J]. SEMINARS IN RADIATION ONCOLOGY, 1997, 7 (03) : 4 - 7
  • [35] TRIPLE THERAPY FOR ADVANCED CANCER OF THE HEAD AND NECK
    CHANDLER, JR
    TEJADA, FJ
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1981, 107 (01) : 27 - 29
  • [36] Planned neck dissection following chemoradiotherapy for advanced head and heck cancer:: Is it necessary for all?
    Pellitteri, PK
    Ferlito, A
    Rinaldo, A
    Shah, JP
    Weber, RS
    Lowry, J
    Medina, JE
    Gourin, CG
    Robbins, KT
    Suárez, C
    Shaha, AR
    Genden, EM
    Leemans, CR
    Lefebvre, JL
    Kowalski, LP
    Wei, WI
    [J]. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2006, 28 (02): : 166 - 175
  • [37] Adjuvant Intraoperative Photodynamic Therapy in Head and Neck Cancer
    Rigual, Nestor R.
    Shafirstein, Gal
    Frustino, Jennifer
    Seshadri, Mukund
    Cooper, Michele
    Wilding, Gregory
    Sullivan, Maureen A.
    Henderson, Barbara
    [J]. JAMA OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2013, 139 (07) : 706 - 711
  • [38] Efficacy of targeted chemoradiation and planned selective neck dissection to control bulky nodal disease in advanced head and neck cancer
    Robbins, KT
    Wong, FSH
    Kumar, P
    Hartsell, WF
    Vieira, F
    Mullins, B
    Niell, HB
    [J]. ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1999, 125 (06) : 670 - 675
  • [39] "Neck dissection" of the residually positive neck after primary radiochemotherapy for locally advanced head and neck cancer
    Christiansen, H.
    Roedel, R. M. W.
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (05) : 444 - 445